WO2009155070A2 - Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques - Google Patents

Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques Download PDF

Info

Publication number
WO2009155070A2
WO2009155070A2 PCT/US2009/045520 US2009045520W WO2009155070A2 WO 2009155070 A2 WO2009155070 A2 WO 2009155070A2 US 2009045520 W US2009045520 W US 2009045520W WO 2009155070 A2 WO2009155070 A2 WO 2009155070A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
nvx
treatment
mammal
disorder
Prior art date
Application number
PCT/US2009/045520
Other languages
English (en)
Other versions
WO2009155070A3 (fr
Inventor
M.D. Burkhard Jansen
Original Assignee
Novelix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelix Pharmaceuticals, Inc. filed Critical Novelix Pharmaceuticals, Inc.
Priority to US12/995,116 priority Critical patent/US20110077297A1/en
Priority to AU2009260485A priority patent/AU2009260485B2/en
Priority to EP09767381A priority patent/EP2303280A2/fr
Publication of WO2009155070A2 publication Critical patent/WO2009155070A2/fr
Publication of WO2009155070A3 publication Critical patent/WO2009155070A3/fr
Priority to US14/553,357 priority patent/US20150306110A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne un procédé de traitement d’inflammation et de lésions hyperkératotiques chez un mammifère qui en a besoin, par l’administration du composé selon l’invention, d’un composé associé ou d’un sel pharmaceutiquement acceptable de celui-ci au mammifère.
PCT/US2009/045520 2008-05-30 2009-05-28 Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques WO2009155070A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/995,116 US20110077297A1 (en) 2008-05-30 2009-05-28 Compositions and methods for treatment of inflammation and hyperkeratotic lesions
AU2009260485A AU2009260485B2 (en) 2008-05-30 2009-05-28 Compositions and methods for treatment of inflammation and hyperkeratotic lesions
EP09767381A EP2303280A2 (fr) 2008-05-30 2009-05-28 Compositions et procédés pour le traitement d inflammation et de lésions hyperkératotiques
US14/553,357 US20150306110A1 (en) 2008-05-30 2014-11-25 Compositions and methods for treatment of inflammation and hyperkeratotic lesions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5769608P 2008-05-30 2008-05-30
US61/057,696 2008-05-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/995,116 A-371-Of-International US20110077297A1 (en) 2008-05-30 2009-05-28 Compositions and methods for treatment of inflammation and hyperkeratotic lesions
US14/553,357 Continuation US20150306110A1 (en) 2008-05-30 2014-11-25 Compositions and methods for treatment of inflammation and hyperkeratotic lesions

Publications (2)

Publication Number Publication Date
WO2009155070A2 true WO2009155070A2 (fr) 2009-12-23
WO2009155070A3 WO2009155070A3 (fr) 2010-02-11

Family

ID=40909946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/045520 WO2009155070A2 (fr) 2008-05-30 2009-05-28 Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques

Country Status (4)

Country Link
US (2) US20110077297A1 (fr)
EP (2) EP2303280A2 (fr)
AU (1) AU2009260485B2 (fr)
WO (1) WO2009155070A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222270B2 (en) 2008-12-19 2012-07-17 Medicis Pharmaceutical Corporation 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod
US8598196B2 (en) 2008-08-18 2013-12-03 Medicis Pharmaceutical Corporation Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US8642616B2 (en) 2009-07-13 2014-02-04 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013318338B2 (en) * 2012-09-21 2017-05-25 Intensity Therapeutics, Inc Method of treating cancer
US20220296610A1 (en) * 2017-04-06 2022-09-22 Derm-Biome Pharmaceuticals Inc. Compositions and methods for treatment of infection and novel cosmeceutical preparations
CN109674799B (zh) * 2019-01-31 2020-10-16 湖南农业大学 桦木酸在机体排铅以及制备排铅食品、保健品和药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014872A1 (fr) * 1994-11-11 1996-05-23 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Nouveaux complexes et compositions les contenant
WO1998032443A1 (fr) * 1997-01-24 1998-07-30 Marigen S.A. Ultramicro-emulsions de concentres spontanement dispersibles renfermant des esters de triterpenes pentacycliques a activite antitumorale, antivirale et antiparasitaire
WO2005077377A1 (fr) * 2004-02-06 2005-08-25 Regents Of The University Of Minnesota Compositions comprenant un triterpene et un excipient
US7312205B2 (en) * 2003-02-11 2007-12-25 Novelix Pharmaceuticals, Inc. Methods and compositions for inhibiting tumor growth

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962527A (en) * 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
EP1309605A1 (fr) * 2000-08-18 2003-05-14 The Board Of Trustees Of The University Of Illinois Promedicaments de derives de l'acide betulinique pour le traitement du cancer et du vih
US20050227929A1 (en) * 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
US20060252733A1 (en) * 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014872A1 (fr) * 1994-11-11 1996-05-23 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Nouveaux complexes et compositions les contenant
WO1998032443A1 (fr) * 1997-01-24 1998-07-30 Marigen S.A. Ultramicro-emulsions de concentres spontanement dispersibles renfermant des esters de triterpenes pentacycliques a activite antitumorale, antivirale et antiparasitaire
US7312205B2 (en) * 2003-02-11 2007-12-25 Novelix Pharmaceuticals, Inc. Methods and compositions for inhibiting tumor growth
WO2005077377A1 (fr) * 2004-02-06 2005-08-25 Regents Of The University Of Minnesota Compositions comprenant un triterpene et un excipient

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271973B2 (en) 2008-08-18 2016-03-01 Medicis Pharmaceutical Corporation Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US8598196B2 (en) 2008-08-18 2013-12-03 Medicis Pharmaceutical Corporation Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US10238644B2 (en) 2008-12-19 2019-03-26 Medicis Pharmaceutical Corporation 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
US8299109B2 (en) 2008-12-19 2012-10-30 Medicis Pharmaceutical Corporation Method of treating actinic keratosis with 3.75% imiquimod cream
US9370509B2 (en) 2008-12-19 2016-06-21 Medicis Pharmaceutical Corporation 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
US11318130B2 (en) 2008-12-19 2022-05-03 Medicis Pharmaceutical Corporation 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
US8236816B2 (en) 2008-12-19 2012-08-07 Medicis Pharmaceutical Corporation 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
US8222270B2 (en) 2008-12-19 2012-07-17 Medicis Pharmaceutical Corporation 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod
US8642616B2 (en) 2009-07-13 2014-02-04 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US10238645B2 (en) 2009-07-13 2019-03-26 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US9980955B2 (en) 2009-07-13 2018-05-29 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US10918635B2 (en) 2009-07-13 2021-02-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US9078889B2 (en) 2009-07-13 2015-07-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US11850245B2 (en) 2009-07-13 2023-12-26 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts

Also Published As

Publication number Publication date
AU2009260485A1 (en) 2009-12-23
US20110077297A1 (en) 2011-03-31
EP2303280A2 (fr) 2011-04-06
EP2371368A3 (fr) 2012-08-22
EP2371368A2 (fr) 2011-10-05
AU2009260485B2 (en) 2015-01-29
US20150306110A1 (en) 2015-10-29
WO2009155070A3 (fr) 2010-02-11

Similar Documents

Publication Publication Date Title
US20150306110A1 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
AU2014224111B2 (en) Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
US9839638B2 (en) Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US10130648B2 (en) Therapeutic composition
CN106456662A (zh) 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
JP2012236857A (ja) 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ
JP4708569B2 (ja) 血管形成を伴う疾患の治療に対する併用
CN101522692A (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药
Borkar et al. Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
Pittalà et al. Effects of novel hybrids of caffeic acid phenethyl ester and NSAIDs on experimental ocular inflammation
Gobert et al. The ability of WAY100, 635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224, 289, but not BRL15572
WO2018203127A1 (fr) Compositions pour le traitement de tumeurs malignes et d'états précancéreux, procédés d'utilisation de celles-ci et procédés de fabrication de médicaments
AU2006214515A1 (en) Use of estrogen receptor-b selective agonists for radiation-or chemotherapy-induced mucosistis and radiation cystitis
US11278542B2 (en) Use of nicotinamide composition in preparation of drug for treating hand-foot skin reaction induced by sorafenib
CN113101289A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
US9050305B2 (en) Treatment for ischemic stroke
JP2019512536A (ja) 局所投与のための安定な医薬組成物およびその使用
WO2019032411A1 (fr) Compositions et procédés permettant d'induire l'apoptose dans des cellules anaérobies et procédés cliniques associés pour le traitement du cancer et d'infections pathogènes
JP2019529558A (ja) 組織の再生の刺激および促進
TW201444561A (zh) 可治療癌症之藥學組合物
US20230172960A1 (en) Topical capecitabine for the treatment of hyperproliferative skin conditions
CN103260614B (zh) 联合疗法
WO2023178255A1 (fr) Combinaisons comprenant des inhibiteurs de metap2 pour le traitement du cancer
JP2020117489A (ja) 脳癌の治療方法
TW202241421A (zh) 菸鹼醯胺及含有其的組合物的製藥用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09767381

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009260485

Country of ref document: AU

Ref document number: 12995116

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009260485

Country of ref document: AU

Date of ref document: 20090528

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009767381

Country of ref document: EP